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Data on the association of CYP2C9 genetic polymorphisms with sulfonylurea (SU)-induced
hypoglycaemia (SH) are inconsistent. Recent studies showed that variants in the P450 oxidore-
ductase (POR) gene could affect CYP2C9 activity. In this study, we explored the effects of
POR*28 and combined CYP2C9*2 and CYP2C9*3 genotypes on SH and the efficacy of SU
treatment in type 2 diabetes. A total of 1770 patients were included in the analysis of SU effi-
cacy, assessed as the combined outcome of the HbA1c reduction and the prescribed SU daily
dose. Sixty-nine patients with severe SH were compared with 311 control patients. The num-
ber of CYP2C9 deficient alleles was associated with nearly three-fold higher odds of hypogly-
caemia (OR, 2.81; 95% CI, 1.30-6.09; P = .009) and better response to SU treatment (β,
−0.218; SE, 0.074; P = .003) only in patients carrying the POR*1/*1 genotype. Our results indi-
cate that interaction between CYP2C9 and POR genes may be an important determinant of
efficacy and severe adverse effects of SU treatment.
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1 | INTRODUCTION
Despite development of novel pharmacological agents, sulfonylureas
(SUs) continue to be a cornerstone in type 2 diabetes (T2D) treat-
ment. The most common and potentially most serious adverse effect
of sulfonylurea therapy is hypoglycaemia, which limits their use.1
Severe hypoglycaemia may result in significant morbidity, including
higher risk of dementia, stroke and mortality.2–4 In addition to estab-
lished clinical factors, identification of genetic factors which can
increase the risk of hypoglycaemia can contribute to safer treatment
with SU agents.
SUs are metabolized in the liver primarily by the CYP2C9
enzyme.5 CYP2C9 is highly polymorphic, with CYP2C9*1 as a major
allele. The 2 most common variants, CYP2C9*2 (R144C, rs1799853)
and CYP2C9*3 (I359L, rs1057910), have been associated with
impaired function and poor metabolism phenotypes6 (Table S1). The
impact of *2 and *3 polymorphisms on the pharmacokinetics of
SUs has been demonstrated in studies in healthy subjects.7 In the
largest study to date on the effect of CYP2C9 variants on therapeu-
tic response to SUs, we showed an association of CYP2C9*2 and
CYP2C9*3 alleles with greater glycaemic response to SUs and a
lower rate of treatment failure,8 confirming earlier pharmacokinetic
data. In line with this, in the Rotterdam study, patients with T2D
carrying the CYP2C9*3 allele required a lower dose of tolbutamide
to regulate glycaemia, compared to patients with the wild-type
CYP2C9 genotype.9
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Despite these findings, limited data from small-sized studies have
not provided convincing evidence of the association between
CYP2C9 poor-metabolizer genotypes and the risk of SU-induced
hypoglycaemia.10 A small study recently showed that a common poly-
morphism in the gene encoding a CYP450 redox partner, enzyme
P450 oxidoreductase (POR), POR*28 (A503V, rs1057868), could
mask the effect of CYP2C9 variants on the risk of hypoglycaemia
associated with SU treatment.11 POR transfers electrons from
NADPH to the CYP450 enzymes and is essential for their activity.
The common POR*28 variant showed modest increase in CYP2C9-
mediated metabolism of 3 different model substrates in an in vitro
study.12 In line with this, the effect of CYP2C9 reduced-function var-
iants on CYP2C9 activity may manifest only in combination with the
POR*1/*1 genotype.11
In this study, we aimed to assess the impact of CYP2C9*2,
CYP2C9*3 and POR*28 alleles, and their interaction, on SU-induced
hypoglycaemia in patients with T2D. Furthermore, we explored the
association of the CYP2C9 and POR variants with the efficacy of SU
treatment in T2D.
2 | METHODS
We used the Scottish Ambulance Service (SAS) data and the Accident
and Emergency (A and E) diagnosis records to identify cases of severe
hypoglycaemia in Tayside and Fife, Scotland. These data were linked
to the Genetics of Diabetes Audit and Research Tayside Study
(GoDARTS) database, which contains genetic information and longi-
tudinal biochemistry records, prescriptions and other clinical data in
an anonymized form, on nearly 10 000 patients with T2D in Tayside,
from 1992 onwards. The GoDARTS study was approved by the Tay-
side Medical Ethics Committee. Informed consent was obtained for
all participants. The use of the GoDARTS bioresource for the study
of diabetes pharmacogenetics was approved by the Tayside
Tissue Bank.
We identified a total of 339 patients with T2D who were under
treatment with SUs, and had experienced a hypoglycaemic event
requiring medical assistance in the period 2008 to 2015. Among
these, there were 69 patients who were in the GoDARTS study and
for whom genetic data were available. Between 1 and 5 controls
were selected for each case from the patients with T2D who had
experienced no hypoglycaemic events and were treated with SUs
during the same time period. These controls were matched for age,
sex and age of T2D diagnosis. Patients treated with insulin were
excluded. The date of the SAS attendance or A and E admission was
taken as an index date for cases and their respective controls.
The pharmacogenetic study of SU response in the GoDARTS
study was described previously in detail.8 In the current study, we
included 1770 patients with T2D who were incident users of SUs
during the period 1994 to 2010. SU response was defined as the dif-
ference between pre-treatment HbA1c and the minimum HbA1c
measured within 1 to 18 months after initiation of SU. Linear regres-
sion was used to model the outcome of HbA1c reduction, using pre-
treatment HbA1c, age, sex, BMI, adherence, average daily dose, base-
line gap (time between pre-treatment HbA1c measurement and
initiation of SU therapy) and a treatment group (SU prescribed as
monotherapy or dual therapy: SU added to stable metformin treat-
ment) as covariates.
In addition to HbA1c reduction, we used 2 other outcomes for
efficacy, to take into account both HbA1c reduction and dosing of
SU as composite measures of response: (1) the average prescribed
dose of SU in the treatment period until minimum HbA1c was
achieved and (2) a combined outcome of HbA1c reduction and pre-
scribed SU daily dose, assessed as an aggregated Z-score:
Combined Z-score=
dose–mean doseð Þ
SD doseð Þ –
ΔHbA1c–mean ΔHbA1cð Þ
SD ΔHbA1cð Þ
Thus, a lower combined Z-score indicates a better response to
SU treatment. As patients were treated with different SU drugs, the
prescribed daily dose was expressed as the percentage of maximum
daily dose recommended by the British National Formulary.
The genotypes for CYP2C9*2, CYP2C9*3 and POR*28 variants
were obtained from existing genome-wide data.13 The frequencies of
the minor alleles of CYP2C9*2, CYP2C9*3 and POR*28 were 12%,
7% and 27%, respectively. There was no deviation from Hardy–
Weinberg equilibrium for any polymorphism. The genotypes for
CYP2C9*2 and CYP2C9*3 were combined and analysed as the num-
ber of the CYP2C9*2 and CYP2C9*3 reduced-function alleles: 0 (*1/
*1), 1 (*1/*2, *1/*3) or 2 (*2/*2, *2/*3, *3/*3), in line with our previ-
ous study.8 An additive genetic model was used to assess the impact
of the POR*28 variant, and the number of CYP2C9 reduced-function
alleles, on hypoglycaemia and SU treatment outcomes.
Conditional logistic regression was used to analyse the effect of
the genotypes on hypoglycaemia. The interaction between POR and
CYP2C9 combined genotypes was assessed by adding an interaction
term to the regression model. In the analyses stratified by genotype,
matching was broken and an unconditional logistic regression was
used. All analyses were adjusted for age, sex, age of T2D diagnosis,
BMI, creatinine and HbA1c. Statistical analysis was performed using
SAS 9.3 software (SAS Institute Inc., Cary, North Carolina). The statis-
tical significance level was set to P < .05.
3 | RESULTS
The characteristics of patients with and without hypoglycaemia are
shown in Table S2. Compared to control patients, patients with hypo-
glycaemia had lower BMI, lower HbA1c and higher creatinine levels.
There was no difference in co-treatment with medications known to
be CYP2C9 inhibitors.
When assessed individually in the conditional logistic regression
model, none of the variants showed association with hypoglycaemia
(Table S3). Next, we explored the interaction between combined
CYP2C9 and POR genotypes by adding an interaction term to the
model. The interaction between the 2 genes was significant
(P = .007). In the analysis stratified by the POR genotypes, the num-
ber of CYP2C9 deficient alleles increased the odds of hypoglycaemia
nearly 3-fold (OR, 2.81; 95% CI, 1.30-6.09; P = .009) in the POR*1/
*1 genotype group, whereas there was no effect in the POR*28
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variant carriers (Table 1). However, when stratified by CYP2C9 geno-
types, the minor POR*28 allele showed no association with hypogly-
caemia in either group (Table 1).
We tested the association of genotypes with SU response
assessed as 3 different endpoints. The characteristics of patients
included in the analysis are presented in Table S4. The effects of var-
iants on the 3 outcomes are shown in Table S5. The CYP2C9*3 vari-
ant (β, 0.145; SE, 0.063; P = .022) and the number of CYP2C9
reduced-function alleles (β, 0.098; SE, 0.041; P = .017) were associ-
ated with better SU response, assessed as HbA1c reduction, in line
with our previous study.8 No variant showed any effect on prescribed
SU dose, whilst POR*28 showed a marginal association with a lower
combined Z-score (β, −0.091; SE, 0.045; P = .043) and thus better
response to SU treatment (Table S5).
There was a significant interaction between CYP2C9 and POR
genotypes, with both the prescribed dose (P = .004) and the com-
bined Z-score (P = .005) outcomes, but not with the simple reduction
in HbA1c outcome (P = .484). In the stratified analysis, the reduced-
function CYP2C9 alleles were associated with a lower combined Z-
score (greater response) only in patients with the POR *1/*1 geno-
type (β, −0.218; SE, 0.074; P = .003) (Table 2). On the other hand, the
POR*28 allele showed association with better response only in
CYP2C9*1/*1 carriers (β, −0.167; SE, 0.058; P = .004) (Table 2).
4 | CONCLUSIONS
Although earlier studies demonstrated the influence of CYP2C9
genetic polymorphisms on the metabolism and glycaemic response to
SUs, data on the association between CYP2C9 genotypes and SU-
induced hypoglycaemia are limited and inconsistent.10 The results of
our study indicate that these discrepancies could be explained, at
least in part, by the interaction between CYP2C9 and POR genes.
Although CYP2C9 deficient alleles were not associated with hypogly-
caemia in the entire group of patients, they increased the odds of
hypoglycaemic events in patients carrying the POR*1/*1 genotype.
Thus, we replicated a finding from the small study by Ragia et al.11
which showed an association between the CYP2C9*2 allele and
higher risk of hypoglycaemia only in POR*1/*1 carriers.
Consistent with the effect on hypoglycaemia, the interaction
between CYP2C9 and POR genes also showed an association with
the efficacy of SU treatment, assessed as a combined outcome of
HbA1c reduction and prescribed SU daily dose. The CYP2C9 deficient
alleles were associated with a better treatment effect in POR*1/*1
carriers. This analysis of SU response in a much larger number of
patients corroborates our findings for SU-induced hypoglycaemia,
which was explored in a smaller cohort.
In line with a previous study,11 the common POR*28 variant was
not associated with hypoglycaemia in the entire group of patients, nor
in subgroups stratified by the CYP2C9 genotype. On the other hand, it
showed an effect on better treatment response in CYP2C9*1/*1 car-
riers. This finding is in contrast to prior in vitro work, where POR*28
showed a modest increase in CYP2C9 activity, with flurbiprofen, diclo-
fenac and tolbutamide as substrates.12 Our results, on the contrary,
imply that POR*28 could possibly lead to decreased activity of the wild-
type CYP2C9, and thus to a higher concentration and an enhanced
effect of SUs. Although this effect is possible, as it has been demon-
strated that the impact of POR variants on CYP activities varies with
the CYP isoform and the tested substrate,14 these intriguing results
have not been replicated and have to be considered with caution.
In conclusion, we have shown that interaction between the
CYP2C9 and POR genes affects the risk of SU-induced hypoglycaemia
and the efficacy of SU treatment. These findings can contribute to
unravelling the genetic causes of high inter-individual differences in
the efficacy and severe adverse effects of SU therapy, and may lead
to safer treatment with these agents.
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TABLE 1 Association of CYP2C9 and POR genotypes with SU-
induced hypoglycaemia: analyses stratified according to CYP2C9 and
POR genotypes
Effect of CYP2C9 deficient alleles on hypoglycaemia - analysis
stratified by POR genotype
POR genotype Cases/Controls OR (95% CI) P
POR *1/*1 29/151 2.81 (1.30-6.09) .009
POR *1/*28, *28/*28 33/133 0.70 (0.32-1.57) .390
Effect of POR*28 minor allele on hypoglycaemia - analysis stratified
by CYP2C9 genotype
CYP2C9 genotype
Cases/
Controls OR (95% CI) P
CYP2C9 *1/*1 35/180 1.58 (0.82-3.03) .174
CYP2C9 *2 or *3
carriers
27/104 0.58 (0.26-1.28) .177
TABLE 2 Association of CYP2C9 and POR genotypes with SU
response, assessed as the combined outcome of HbA1c reduction
and prescribed daily dose (combined Z-score): analyses stratified
according to CYP2C9 and POR genotypes
Effect of CYP2C9 deficient alleles on combined Z-score - analysis
stratified by POR genotype
POR genotype N Beta SE P
POR *1/*1 928 −0.218 0.074 .003
POR *1/*28, *28/*28 842 0.035 0.065 .588
Effect of POR*28 minor allele on combined Z-score - analysis
stratified by CYP2C9 genotype
CYP2C9 genotype N Beta SE P
CYP2C9 *1/*1 1130 −0.167 0.058 .004
CYP2C9 *2 or *3 carriers 640 0.059 0.071 .412
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